Literature DB >> 31688719

Safety and Effectiveness of Same-Day Chlamydia trachomatis and Neisseria gonorrhoeae Screening and Treatment Among Gay, Bisexual, Transgender, and Homeless Youth in Los Angeles, California, and New Orleans, Louisiana.

Erin M Keizur1, Cameron Goldbeck2, Gabriella Vavala1, Adriana Romero-Espinoza2, Manuel Ocasio3, Jasmine Fournier3, Sung-Jae Lee2, Sue-Ellen Abdalian3, Mary Jane Rotheram2, Jeffrey D Klausner1.   

Abstract

BACKGROUND: Gay, bisexual, transgender, and homeless youth are at risk of sexually transmitted infections. As part of an adolescent human immunodeficiency virus prevention study, we provided same-day Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) testing and treatment. We aimed to evaluate the feasibility and effectiveness of same-day CT and NG treatment on the proportion of participants receiving timely treatment.
METHODS: We recruited adolescents with high sexual risk behaviors aged 12 to 24 years from homeless shelters, lesbian, gay, bisexual, and transgender organizations, and community health centers in Los Angeles, California, and New Orleans, Louisiana from May 2017 to June 2019. Initially, participants were offered point-of-care pharyngeal, rectal, and urethral/vaginal CT and NG testing and referral to another clinic for treatment. After March 2018 in Los Angeles and November 2018 in New Orleans, we provided same-day treatment (and partner treatment packs) for study participants. We measured the proportion of participants who received same-day treatment and the median time to treatment. We collected frequency of partner treatment and any reported adverse treatment-related events.
RESULTS: The proportion of participants receiving same-day CT and NG treatment increased from 3.6% (5/140) to 21.1% (20/95; Δ17.5%; 95% confidence interval, 9.2%-26.9%) after implementation of same-day testing and treatment. The median time to treatment decreased from 18.5 to 3 days. Overall, 36 participants took a total of 48 partner treatment packs. There were no reported treatment-related adverse events.
CONCLUSIONS: Providing sexually transmitted infection treatment to adolescents at the same visit as testing is feasible and safe, and can increase the proportion of individuals receiving timely treatment.

Entities:  

Mesh:

Year:  2020        PMID: 31688719      PMCID: PMC6923576          DOI: 10.1097/OLQ.0000000000001088

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   3.868


  21 in total

1.  Empiric treatment of sexually transmitted infections in a pediatric Emergency Department: are we making the right decisions?

Authors:  Amy E Pattishall; Shahnaz Y Rahman; Shabnam Jain; Harold K Simon
Journal:  Am J Emerg Med       Date:  2011-12-12       Impact factor: 2.469

2.  A model of sexual risk behaviors among young gay and bisexual men: longitudinal associations of mental health, substance abuse, sexual abuse, and the coming-out process.

Authors:  Margaret Rosario; Eric W Schrimshaw; Joyce Hunter
Journal:  AIDS Educ Prev       Date:  2006-10

3.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

4.  Gaps in Chlamydia Treatment Within California Family Planning Clinics: Are Patients Filling Prescriptions?

Authors:  Laura Kovaleski; Claire Feldman; Scott Baker; Holly Howard; Aileen Barandas; Joan Chow; Heidi Bauer
Journal:  Sex Transm Dis       Date:  2019-06       Impact factor: 2.830

5.  The cost and cost-effectiveness of expedited partner therapy compared with standard partner referral for the treatment of chlamydia or gonorrhea.

Authors:  Thomas L Gift; Patricia Kissinger; Hamish Mohammed; Jami S Leichliter; Matthew Hogben; Matthew R Golden
Journal:  Sex Transm Dis       Date:  2011-11       Impact factor: 2.830

6.  Performance of the Cepheid CT/NG Xpert Rapid PCR Test for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae.

Authors:  Charlotte A Gaydos; Barbara Van Der Pol; Mary Jett-Goheen; Mathilda Barnes; Nicole Quinn; Carey Clark; Grace E Daniel; Paula B Dixon; Edward W Hook
Journal:  J Clin Microbiol       Date:  2013-03-06       Impact factor: 5.948

7.  Confidentiality Issues and Use of Sexually Transmitted Disease Services Among Sexually Experienced Persons Aged 15-25 Years - United States, 2013-2015.

Authors:  Jami S Leichliter; Casey Copen; Patricia J Dittus
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-03-10       Impact factor: 17.586

8.  Development of an Electronic Data Collection System to Support a Large-Scale HIV Behavioral Intervention Trial: Protocol for an Electronic Data Collection System.

Authors:  W Scott Comulada; Wenze Tang; Dallas Swendeman; Amy Cooper; Jeremy Wacksman
Journal:  JMIR Res Protoc       Date:  2018-12-14

Review 9.  A Systematic Review of Point of Care Testing for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis.

Authors:  Sasha Herbst de Cortina; Claire C Bristow; Dvora Joseph Davey; Jeffrey D Klausner
Journal:  Infect Dis Obstet Gynecol       Date:  2016-05-26

10.  Rapid testing and treatment for sexually transmitted infections improve patient care and yield public health benefits.

Authors:  Gary G Whitlock; Daniel C Gibbons; Nick Longford; Michael J Harvey; Alan McOwan; Elisabeth J Adams
Journal:  Int J STD AIDS       Date:  2017-10-23       Impact factor: 1.359

View more
  8 in total

Review 1.  Diagnostic Tests for Detecting Chlamydia trachomatis and Neisseria gonorrhoeae in Rectal and Pharyngeal Specimens.

Authors:  Paul C Adamson; Jeffrey D Klausner
Journal:  J Clin Microbiol       Date:  2021-11-03       Impact factor: 11.677

Review 2.  Point-of-Care Testing for Sexually Transmitted Infections: A Review of Recent Developments.

Authors:  Paul C Adamson; Michael J Loeffelholz; Jeffrey D Klausner
Journal:  Arch Pathol Lab Med       Date:  2020-11-01       Impact factor: 5.534

3.  Optimizing Screening for Anorectal, Pharyngeal, and Urogenital Chlamydia trachomatis and Neisseria gonorrhoeae Infections in At-Risk Adolescents and Young Adults in New Orleans, Louisiana and Los Angeles, California, United States.

Authors:  Olivia M Man; Wilson E Ramos; Gabriella Vavala; Cameron Goldbeck; Manuel A Ocasio; Jasmine Fournier; Adriana Romero-Espinoza; M Isabel Fernandez; Dallas Swendeman; Sung-Jae Lee; Scott Comulada; Mary Jane Rotheram-Borus; Jeffrey D Klausner
Journal:  Clin Infect Dis       Date:  2021-11-02       Impact factor: 9.079

Review 4.  Appropriate Use and Future Directions of Molecular Diagnostic Testing.

Authors:  Erin H Graf; Preeti Pancholi
Journal:  Curr Infect Dis Rep       Date:  2020-02-06       Impact factor: 3.725

5.  Molecular chlamydia and gonorrhoea point of care tests implemented into routine practice: Systematic review and value proposition development.

Authors:  Sebastian S Fuller; Eleanor Clarke; Emma M Harding-Esch
Journal:  PLoS One       Date:  2021-11-08       Impact factor: 3.240

6.  What can be learnt from a qualitative evaluation of implementing a rapid sexual health testing, diagnosis and treatment service?

Authors:  Ava Lorenc; Emer Brangan; Joanna M Kesten; Paddy J Horner; Michael Clarke; Megan Crofts; Jonathan Steer; Jonathan Turner; Peter Muir; Jeremy Horwood
Journal:  BMJ Open       Date:  2021-10-22       Impact factor: 3.006

7.  Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae in the homeless population of Medellín, Colombia: a cross-sectional study.

Authors:  Diego Enrique Vélez-Gómez; Natalia Torres-Vellojín; Juan Camilo Grajales-Zapata; Juan Guillermo McEwen-Ochoa; Alonso Martínez; Verónica Ramírez-Lopera; Aracelly Villegas-Castaño
Journal:  BMJ Open       Date:  2022-03-01       Impact factor: 2.692

Review 8.  Controversies and evidence on Chlamydia testing and treatment in asymptomatic women and men who have sex with men: a narrative review.

Authors:  Nicole H T M Dukers-Muijrers; Ymke J Evers; Christian J P A Hoebe; Petra F G Wolffs; Henry J C de Vries; Bernice Hoenderboom; Marianne A B van der Sande; Janneke Heijne; Jeffrey D Klausner; Jane S Hocking; Jan van Bergen
Journal:  BMC Infect Dis       Date:  2022-03-14       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.